Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
171
resultados
Última actualización
13/09/2025 [07:54:00]
Resultados 25 a 50 de 171
Resumen de: WO2025183416A1
The present invention relates to a composition for treating cognitive dysfunction, specifically Alzheimer's disease. The composition according to one aspect can inhibit or reduce the accumulation of amyloid aggregates and phosphorylated tau aggregates, and improve memory and cognitive function.
Resumen de: WO2025184593A1
The present disclosure provides methods for preventing or treating a neurodegenerative disorder in a subject, where the neurodegenerative disorder is one characterized by a deposition of abnormal tau protein in the brain of the subject. The method generally includes administering to the subject a therapeutically effective amount of a drug that is a tau propagation antagonist.
Resumen de: WO2025184649A1
The present disclosure provides methods related to treating neurodegeneration and neuroinflammation. In particular, the present disclosure identifies YTH domain-containing family protein 1 (YTHDF1) as a novel therapeutic target for Alzheimer's disease. Embodiments of the present disclosure provide methods of therapy for neurodegenerative disease that involve inhibiting YTHDF1 to induce attenuation of chronic neuroinflammation.
Resumen de: WO2025181155A1
This application relates to polypeptide agents and compositions specifically binding human beta-glucocerebrosidase (GCase, GBA1). Particularly, immunoglobulin single variable domains (ISVDs) are described which allosterically bind human GCase, thereby positively modulating GCase in its stability and/or catalytic activity. The invention relates further to vectors and nucleic acids encoding such ISVD-based modulators. Also encompassed are compositions, in particular pharmaceutical compositions, containing such ISVD modulators. The GCase-specific allosteric modulators, specifically the ISVDs and compositions described herein, may be used for prevention and/or treatment of GCase-related diseases, including Gaucher disease (GD) and Parkinson's disease (PD).
Resumen de: WO2025184490A1
The present disclosure provides methods of treating Alzheimer's Disease (AD) using Compound (I) as represented by the structure below: Formula should be inserted here or a free base or pharmaceutically acceptable salt thereof.
Resumen de: US2025277040A1
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Resumen de: AU2025213702A1
Abstract Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease. Abstract Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.
Resumen de: AU2025217319A1
Described herein are methods for treating a subject having or at risk of developing Parkinson’s disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents. Described herein are methods for treating a subject having or at risk of developing Parkinson's disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents. ug e s c r i b e d h e r e i n a r e m e t h o d s f o r t r e a t i n g a s u b j e c t h a v i n g o r a t r i s k o f d e v e l o p i n g u g a r k i n s o n ' s d i s e a s e , b y a d m i n i s t e r i n g p l u r i p o t e n t c e l l s t h a t e x p r e s s g l u c o c e r e b r o s i d a s e ( ) o r p l u r i p o t e n t c e l l s t h a t e x p r e s s a n d o n e o r m o r e - p r o m o t i n g a g e n t s t o t h e s u b j e c t l s o d i s c l o s e d a r e c o m p o s i t i o n s c o m p r i s i n g p l u r i p o t e n t c e l l s e x p r e s s i n g , s u c h a s p l u r i p o t e n t c e l l s e x p r e s s i n g a n d o n e o r m
Resumen de: US2025277203A1
The invention relates to expression vectors, and pharmaceutical compositions, and kits comprising the vectors, and, in particular, their use in methods for treating Parkinson's disease (PD), DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.
Resumen de: US2025275953A1
The present disclosure relates to a method of treating, or delaying, inhibiting, or suppressing of the progression of, a neurodegenerative disease such as, for example, early-stage Parkinson's disease comprising administering a c-Abl inhibitor (such as vodobatinib, or a pharmaceutically acceptable salt thereof) to a subject in need thereof.
Resumen de: US2025276011A1
The present disclosure provides, among other things, methods for the treatment of neurodegenerative diseases (ND) and other mitochondrial disorders, and compositions related thereto. Described herein are in vitro (cell culture) and in vivo (animal model) experimental examples demonstrating mitochondrial organelle transplantation (MOT) for the treatment of NDs such as amyotrophic lateral sclerosis (ALS). Furthermore, as discussed herein, MOT has been performed in five human ALS patients with positive results—measurable improvement of their conditions has been observed, with no adverse events.
Resumen de: US2025275936A1
Compositions and methods for treating a cancer or a neurological disease. A method of treating a cancer or a neurological disease comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin C, folic acid, a chemotherapeutic agent, and zafirlukast. A method of treating amyotrophic lateral sclerosis comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin C, folic acid, a chemotherapeutic agent, and zafirlukast.
Resumen de: US2025275935A1
Compositions and products (e.g., kits, medical devices, medicaments), which incorporate the compositions, comprising a tetrahydrocannabinol (THC) compound and melatonin compound are provided, Methods for treatment using the compositions and products, methods for diagnosis before or after treatment, and processes for formulating the compositions or manufacturing the products are also provided. They address the need for new treatments of cognitive and perceptual deficits, neuropsychiatric symptoms, neurodegenerative diseases, and neurologic disorders. The inventors discovered therapeutically effective amounts of TI-IC and melatonin can be administered to treat patients, without need for an entourage effect or requirement of cannabidiol (CBD) and other cannabinoid compounds. Optionally, polyphenolic compounds (e.g., curcumin-related compounds, rutin-related compounds) and/or Vitamin E-related compounds (e.g., mixed tocopherols, alpha-tocopherol, beta-tocopherol, gamma-tocopherol) may be administered together with or separately from TI-IC and melatonin compounds.
Resumen de: MX2025004703A
Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo3,4-gisoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as. Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.
Resumen de: EP4610260A1
A novel Kv1.3 channel (or KV1.3) inhibitor, which can be used for preventing and/or treating diseases related to the Kv1.3 channel (or Kv1.3), including immune and inflammatory diseases, such as: multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis, and periodontitis; as well as obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, ischemic stroke, etc.
Resumen de: WO2024092001A1
The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti-CD33 antibody or an antigen binding fragment thereof. Alternatively, the methods comprise administering to the subject an effective amount of engineered immune cells expressing a neuronal antigen specific CAR and an anti-CD33 antibody or an antigen binding fragment thereof.
Resumen de: MX2025006287A
The present disclosure relates to compositions comprising trehalose and methods of using same for the treatment of Huntington's disease.
Resumen de: MX2025006419A
Provided herein are methods for treating Alzheimer' s disease using a combination of tramiprosate, a tramiprosate prodrug or an active tramiprosate metabolite with at least one amyloid plaque clearing agent.
Resumen de: MX2025008347A
The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/ Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)ZCoronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
Resumen de: MX2025008949A
Provided herein are RNAi molecules for treating Huntington' s disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
Resumen de: MX2025009625A
HTT nucleic acid trans-splicing molecules are described, which include a coding domain comprising one or more <i>HTT</i> exons, a splice site, and a binding domain that binds a target intron of a <i>HTT</i> pre-mRNA. HTT nucleic acid trans-splicing molecules described herein may also be used in combination with, e.g., MSH3 binding domains arranged in tandem with an HTT binding domain,<i> </i>MSH3 nucleic acid trans-splicing molecules, <i>MSH3</i> splice modulators, anti-sense oligonucleotides or anti-sense RNA to either of <i>MSH3</i> or <i>HTT</i> and <i>MSH3</i> or <i>HTT</i> microRNA (miRNA) and constructs encoding same. Compositions comprising nucleic acid trans-splicing molecules described herein are also encompassed, as are compositions comprising combinations of nucleic acid trans-splicing molecules with additional therapeutic agents (e.g., <i>MSH3</i> nucleic acid trans-splicing molecules, <i>MSH3</i> splice modulators, anti-sense oligonucleotides or anti-sense RNA to either of <i>MSH3</i> or <i>HTT</i>). Nucleic acid trans-splicing molecules may be used alone or in combination with additional therapeutic agents in methods for treating Huntington's Disease (HD). Nucleic acid trans-splicing molecules are also described herein for use, alone or in combination with additional therapeutic agents, in treating HD or in the preparati
Resumen de: US2024342309A1
Disclosed herein are recombinant gene therapy vectors comprising a PTEN-induced kinase 1 (PINK1) encoding gene that is operatively linked to a promoter and methods of using the recombinant therapy vectors for inhibiting, reducing, or delaying degeneration or death of neurons of a subject.
Resumen de: MD20250033A2
Disclosed in the present invention are a cannabinoid composition and an application thereof in the preparation of a drug for treating neurodegenerative diseases, for use in solving the existing problems of large side effects and poorer therapeutic efficacy after long-term use of a drug for treating neurodegenerative diseases. The cannabinoid composition comprises cannabidiol and cannabigerol which are in a mass ratio of 1:1-1:10 or 1:0.3-1:0.5 or 1:0.5-1:0.7 or 1:0.7-1:1. According to the present invention, by using an experimental method for inducing the differentiation of fibroblasts into dopamine nerve cells to observe the morphologies and number of cells after the inducing of cell differentiation and detect an expression level of DA-related factors, and to screen effects of common different cannabinoids and combinations thereof on the inducing of the differentiation of fibroblasts into dopaminergic neurons, it is found that a CBD+CBG combination has optimal effects on the improvement of the survival ability and dopamine secretingability of the dopaminergic neurons, does not contain the addictive substance THC and thus greatly reduces the side effects of a drug, and can be used for preparing a drug for treating neurodegenerative diseases.
Resumen de: KR20250129577A
본 발명은 담수어 가수분해물을 포함하는 알츠하이머성 치매의 예방, 개선 또는 치료용 조성물에 관한 것으로, 보다 상세하게는, 본 발명의 가물치, 동자개, 메기, 무지개송어, 붕어, 쏘가리, 잉어, 향어, 미꾸라지, 또는 빙어 등의 담수어의 효소 가수분해물, 상기 가수분해물로부터 얻은 분획물, 상기 분획물로부터 분리한 펩타이드는 우수한 β-세크레타제 저해 활성을 가지므로, 이들을 알츠하이머성 치매의 예방, 개선 또는 치료를 위한 의약, 식품 등에 활용할 수 있다.
Nº publicación: US2025268911A1 28/08/2025
Solicitante:
WOOLSEY PHARMACEUTICALS INC [US]
Woolsey Pharmaceuticals, Inc
Resumen de: US2025268911A1
Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ≤23 and/or a CDR-SOB score of ≥4.5.
BOPI
Sede Electrónica
